Biontech announces strategic partnership with uk government to provide up to 10,000 patients with personalized mrna cancer immunotherapies by 2030

Mainz, germany, january 6, 2023 – biontech se (nasdaq: bntx, “biontech”, “the company”) today announced that the company signed a memorandum of understanding (“mou”) with the government of the united kingdom (“uk”) to benefit patients by accelerating clinical trials for personalized mrna immunotherapies with the aim to provide personalized cancer therapies for up to 10,000 patients by the end of 2030, either in clinical trials or as authorized treatments. this objective is part of a multi-year collaboration focused on three strategic pillars: cancer immunotherapies based on mrna or other drug classes, infectious disease vaccines, and investments into expanding biontech's footprint in the uk as one of the company's key markets.
BNTX Ratings Summary
BNTX Quant Ranking